The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BNGO | -90.12% | -99.42% | -64.27% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +130% |
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
A CFO departure shines a light on some of the company's recent struggles.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.73M | -13.4% |
| Gross Profit | $3.48M | 34.5% |
| Gross Margin | 51.64% | 18.4% |
| Market Cap | $11.03M | -71.7% |
| Market Cap / Employee | $0.11M | 0.0% |
| Employees | 100 | -70.9% |
| Net Income | -$6.86M | 57.7% |
| EBITDA | -$5.47M | 68.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.56M | -83.4% |
| Accounts Receivable | $3.49M | -44.2% |
| Inventory | 8.6 | -55.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.22M | 7.0% |
| Short Term Debt | $13.36M | -38.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -72.39% | 29.5% |
| Return On Invested Capital | -132.79% | 107.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.49M | 84.5% |
| Operating Free Cash Flow | -$3.49M | 84.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.82 | 0.91 | 0.15 | 0.21 | -55.21% |
| Price to Sales | 1.17 | 1.05 | 0.26 | 0.41 | -67.15% |
| Price to Tangible Book Value | 38.31 | 40.47 | 0.20 | 0.26 | -99.44% |
| Enterprise Value to EBITDA | -1.69 | -4.85 | 0.55 | -0.63 | -75.14% |
| Return on Equity | -161.8% | -170.3% | -127.8% | -118.3% | -14.51% |
| Total Debt | $22.45M | $27.30M | $18.42M | $19.58M | -28.98% |
BNGO earnings call for the period ending December 31, 2024.
BNGO earnings call for the period ending September 30, 2024.
BNGO earnings call for the period ending June 30, 2024.
BNGO earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
